Myomo Inc
F:0M61
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.04
5.07
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one 0M61 stock under the Base Case scenario is 4.73 EUR. Compared to the current market price of 4.42 EUR, Myomo Inc is Undervalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Myomo Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for 0M61 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Myomo Inc
Balance Sheet Decomposition
Myomo Inc
Current Assets | 13.7m |
Cash & Short-Term Investments | 8.9m |
Receivables | 2.4m |
Other Current Assets | 2.4m |
Non-Current Assets | 930.6k |
PP&E | 839.4k |
Other Non-Current Assets | 91.2k |
Current Liabilities | 5.5m |
Accounts Payable | 1.1m |
Accrued Liabilities | 4.3m |
Other Current Liabilities | 105k |
Non-Current Liabilities | 115.2k |
Other Non-Current Liabilities | 115.2k |
Earnings Waterfall
Myomo Inc
Revenue
|
21.1m
USD
|
Cost of Revenue
|
-6.9m
USD
|
Gross Profit
|
14.2m
USD
|
Operating Expenses
|
-23.7m
USD
|
Operating Income
|
-9.5m
USD
|
Other Expenses
|
15k
USD
|
Net Income
|
-9.4m
USD
|
Free Cash Flow Analysis
Myomo Inc
USD | |
Free Cash Flow | USD |
0M61 Profitability Score
Profitability Due Diligence
Myomo Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Myomo Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
0M61 Solvency Score
Solvency Due Diligence
Myomo Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Myomo Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
0M61 Price Targets Summary
Myomo Inc
According to Wall Street analysts, the average 1-year price target for 0M61 is 5.89 EUR with a low forecast of 2.06 EUR and a high forecast of 8.11 EUR.
Dividends
Current shareholder yield for MYO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MYO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.
Contact
IPO
Employees
Officers
The intrinsic value of one 0M61 stock under the Base Case scenario is 4.73 EUR.
Compared to the current market price of 4.42 EUR, Myomo Inc is Undervalued by 7%.